Nivolumab Drug Encyclopedia

Nivolumab (Nivolumab) is an immune checkpoint inhibitor and a new type of targeted therapy drug among anti-cancer drugs. It treats cancer by regulating the immune system. Compared with traditional chemotherapy drugs, its mechanism is more specific and precise, and it can enhance the body's own immune response to cancer cells.

The main mechanism of action of nivolumab is to activate and enhance the patient's own immune system by blocking the PD-1 (programmed death -1) receptor on the immune checkpoint. PD-1 is an immune checkpoint protein. Under normal circumstances, it can inhibit the activity of T cells to prevent overactive autoimmune reactions. However, some tumor cells can use the PD-1 pathway to evade immune system attack, preventing cancer cells from being cleared by the immune system. Nivolumab blocks the binding of PD-1 and its ligand PD-L1 (programmed death ligand -1), releasing the inhibition of T cells, allowing them to recognize, attack and eliminate cancer cells.

Currently, nivolumab has been approved for the treatment of a variety of malignant tumors, including advanced non-small cell lung cancer, melanoma, renal cell carcinoma, Hodgkin lymphoma, head and neck squamous cell carcinoma, etc. Clinical trials have shown that nivolumab shows significant efficacy in many cancer types, extending patient survival and improving quality of life. For some patients with advanced or metastatic tumors, nivolumab is often used as part of maintenance therapy to prolong survival or slow down disease progression.

Although nivolumab has brought new breakthroughs in cancer treatment, its use may be accompanied by some adverse reactions, such as fatigue, rash, digestive tract problems, etc. Therefore, during treatment with nivolumab, patients need to monitor closely and promptly report any discomfort symptoms to their doctors so that the treatment plan can be adjusted in a timely manner to ensure the safety and effectiveness of the treatment.